Last reviewed · How we verify
Exelon
At a glance
| Generic name | Exelon |
|---|---|
| Also known as | rivastigmine |
| Sponsor | US Department of Veterans Affairs |
| Target | Acetylcholinesterase, Cholinesterase, Acetylcholine receptor subunit epsilon |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Alzheimer's disease
- Dementia associated with Parkinson's Disease
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Depression
- Headache
- Anxiety
- Anorexia/Decreased appetite
- Weight decreased
- Dizziness
- Abdominal pain
- Urinary tract infection
- Asthenia
Key clinical trials
- Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment (PHASE1)
- Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease (EARLY_PHASE1)
- Masitinib in Patients With Mild Alzheimer's Disease (PHASE3)
- CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease) (PHASE3)
- Quality Improvement and Practice Based Research in Neurology Using the EMR (PHASE4)
- Rivastigmine for Antimuscarinic Delirium (PHASE2)
- Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium (PHASE2)
- Toward a Computationally-Informed, Personalized Treatment for Hallucinations (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exelon CI brief — competitive landscape report
- Exelon updates RSS · CI watch RSS
- US Department of Veterans Affairs portfolio CI